89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.
舊金山，2024年4月17日（環球新聞專線）——89bio, Inc.（納斯達克股票代碼：ETNB）是一家臨床階段的生物製藥公司，專注於治療肝臟和心臟代謝疾病的創新療法的開發和商業化，今天宣佈任命馬丁·巴布勒爲董事會成員，自2024年4月13日起生效。巴布勒先生是一位非常成功的高管，爲89bio帶來了寶貴的行業經驗，目前擔任Alumis Therapeutics總裁、首席執行官兼董事會主席。
"As 89bio executes on its ongoing Phase 3 programs for pegozafermin, this is an opportune time to add an industry leader like Martin to our board," said Rohan Palekar, Chief Executive Officer of 89bio. "Martin's impressive track record for building and leading companies through commercialization will be invaluable to us at this stage in our development, and we look forward to leveraging his extensive experience and strategic insight to deliver on the full potential of pegozafermin."
89bio首席執行官羅漢·帕萊卡爾表示：“在89bio執行其正在進行的pegozafermin第三階段計劃之際，現在是增加像馬丁這樣的行業領導者加入我們的董事會的好時機。”“在我們現階段的發展階段，馬丁在建立和領導公司商業化方面所取得的令人印象深刻的往績對我們來說將是無價的，我們期待利用他的豐富經驗和戰略洞察力來發揮pegozafermin的全部潛力。”
Mr. Babler brings over 30 years of pharmaceutical and biotech experience. Prior to his role at Alumis Therapeutics, he served as President and CEO of Principia Biopharma, until its acquisition by Sanofi S.A. in September 2020. Prior to Principia Biopharma, Mr. Babler served as President and CEO of Talima Therapeutics from 2007 to 2011. From 1998 to 2007, he held several positions at Genentech, most notably as Vice President, Immunology Sales and Marketing. While at Genentech, he also helped to build and lead the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. Mr. Babler currently serves on the Board of Directors of Prelude Therapeutics Inc., Sardona Therapeutics and the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization, and previously served on the Board of Directors of Neoleukin Therapeutics, Inc. Mr. Babler received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Babler 先生擁有超過 30 年的製藥和生物技術經驗。在Alumis Therapeutics任職之前，他曾擔任Principia Biopharma的總裁兼首席執行官，直到2020年9月被賽諾菲股份公司收購。在加入 Principia Biopharma 之前，Babler 先生於 2007 年至 2011 年擔任 Talima Therapeutics 的總裁兼首席執行官。從1998年到2007年，他在基因泰克擔任過多個職位，最著名的是免疫學銷售和營銷副總裁。在基因泰克任職期間，他還幫助建立和領導了商業開發組織，並領導了心血管營銷組織。Babler 先生之前曾在禮來公司任職，主要負責銷售、銷售管理、全球營銷和業務發展。巴布勒先生目前在Prelude Therapeutics Inc.、Sardona Therapeutics和生物技術創新組織新興公司部理事會任職，此前曾在Neoleukin Therapeutics, Inc.的董事會任職。巴布勒先生獲得了蘇黎世聯邦理工學院的瑞士聯邦藥學文憑，並在西北大學凱洛格管理研究生院完成了高管發展計劃。
"There is a lot of momentum within the metabolic disease space, including indications such as metabolic dysfunction-associated steatohepatitis (MASH), and I'm delighted to join 89bio as they advance pegozafermin, their lead program, through late-stage development," said Mr. Babler. "This is a particularly interesting time for the company as it executes on its Phase 3 program and plans for commercialization. I am excited to work alongside the management team and Board of Directors to bring pegozafermin to the many patients in need."
巴布勒說：“代謝性疾病領域勢頭強勁，包括代謝功能障礙相關性脂肪肝炎（MASH）等適應症，我很高興加入89bio，他們正在推進其主要項目pegozafermin的後期開發。”“對於該公司來說，這是一個特別有趣的時刻，因爲該公司正在執行其第三階段計劃和商業化計劃。我很高興能與管理團隊和董事會合作，將pegozafermin帶給許多有需要的患者。”
About the ENLIGHTEN Program
The ENLIGHTEN program is comprised of two Phase 3 global, multi-center, randomized, double-blind, placebo-controlled trials, evaluating the efficacy and safety of pegozafermin in patients with MASH. The ENLIGHTEN-Fibrosis trial, the first of the two Phase 3 trials in the program, will enroll approximately 1,000 patients with non-cirrhotic MASH (fibrosis stage F2-F3) to evaluate the efficacy and safety of pegozafermin. The co-primary endpoints, for which demonstration of an effect on each is needed to support regulatory approval, measured at week 52 are a one-point improvement in fibrosis with no worsening of MASH and MASH resolution with no worsening of fibrosis, assessed at week 52. ENLIGHTEN-Cirrhosis, the second of the two Phase 3 trials in the program, will evaluate the efficacy and safety of pegozafermin in MASH patients with compensated cirrhosis (F4).
關於 ENLIGHTEN 計劃
ENLIGHTEN計劃包括兩項3期全球、多中心、隨機、雙盲、安慰劑對照試驗，評估pegozafermin對MASH患者的療效和安全性。Enlighten-Fibrosis試驗是該項目兩項3期試驗中的第一項，將招募約1,000名非肝硬化MASH（纖維化階段 F2-F3）患者，以評估pegozafermin的療效和安全性。根據第52周的評估，在第52周測得的共同主要終點是纖維化的一個百分點改善，MASH和MASH分辨率沒有惡化，纖維化沒有惡化，纖維化也沒有惡化。Enlighten-Cirrhosis是該項目兩項3期試驗中的第二項，將評估pegozafermin對MASH代償性肝硬化（F4）患者的療效和安全性。
About pegozafermin
Pegozafermin is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). FGF21 is an endogenous hormone that has broad effects such as regulating energy expenditure, glucose and lipid metabolism. In clinical trials, pegozafermin has demonstrated direct anti-fibrotic and anti-inflammatory effects on the liver, as well as reduced triglyceride levels, improved insulin resistance and glycemic control, and continued to demonstrate a favorable safety and tolerability profile. Pegozafermin received Breakthrough Therapy designation (BTD) status from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) status from the European Medicines Agenda (EMA) for the treatment of MASH with fibrosis.. Pegozafermin is being studied in the Phase 3 ENLIGHTEN trial program for MASH and the Phase 3 ENTRUST trial for SHTG.
關於 pegozafermin
Pegozafermin是一種專門設計的成纖維細胞生長因子21（FGF21）的糖聚糖化類似物，正在開發用於治療代謝功能障礙相關的脂肪性肝炎（MASH）和嚴重的高甘油三酯血癥（SHTG）。FGF21 是一種內源性激素，具有調節能量消耗、葡萄糖和脂質代謝等廣泛作用。在臨床試驗中，pegozafermin已顯示出對肝臟具有直接的抗纖維化和抗炎作用，並降低了甘油三酯水平，改善了胰島素抵抗和血糖控制，並繼續表現出良好的安全性和耐受性。Pegozafermin獲得了美國食品藥品監督管理局（FDA）的突破性療法稱號（BTD）和歐洲藥品議程（EMA）的優先藥物（PRIME）地位，用於治療纖維化MASH。Pegozafermin 正在 MASH 的 3 期 ENLIGHTEN 試驗計劃和 SHTG 的 3 期 ENTRUST 試驗中進行研究。
譯文內容由第三人軟體翻譯。